Small nucleolar RNA signatures as biomarkers for non-small-cell lung cancer

Molecular Cancer

Research

Feng Jiang¹  Jun Shen¹  Jipei Liao¹  Lei Yu¹  Yuping Mei¹  Maria Guarnera¹  Ruiyun Li²  Zhenqiu Liu³ 

[1] Department of Pathology, University of Maryland School of Medicine, Baltimore, MD, USA;Department of Surgery, University of Maryland School of Medicine, Baltimore, MD, USA;Division of Biostatistics of The University of Maryland Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore, MD, USA;

关键词: Chronic Obstructive Pulmonary Disease;    Chronic Obstructive Pulmonary Disease Patient;    NSCLC Patient;    NSCLC Tissue;    Chronic Obstructive Pulmonary Disease Group;   

DOI  :  10.1186/1476-4598-9-198

 received in 2010-05-21, accepted in 2010-07-27,  发布年份 2010

来源: Springer

【 摘 要 】

BackgroundNon-small-cell lung cancer (NSCLC) is the leading cause of cancer death. Early detection of NSCLC will improve its outcome. The current techniques for NSCLC early detection are either invasive or have low accuracy. Molecular analyses of clinical specimens present promising diagnostic approaches. Non-coding RNAs (ncRNAs) play an important role in tumorigenesis and could be developed as biomarkers for cancer. Here we aimed to develop small nucleolar RNAs (snoRNAs), a common class of ncRNAs, as biomarkers for NSCLC early detection. The study comprised three phases: (1) profiling snoRNA signatures in 22 NSCLC tissues and matched noncancerous lung tissues by GeneChip Array, (2) validating expressions of the signatures by RT-qPCR in the tissues, and (3) evaluating plasma expressions of the snoRNAs in 37 NSCLC patients, 26 patients with chronic obstructive pulmonary disease (COPD), and 22 healthy subjects.ResultsIn the surgical tissues, six snoRNAs were identified, which were overexpressed in all tumour tissues compared with their normal counterparts. The overexpressions of the genes in tumors were confirmed by RT-qPCR. The snoRNAs were stably present and reliably detectable in plasma. Of the six genes, three (SNORD33, SNORD66 and SNORD76) displayed higher plasma expressions in NSCLC patients compared with the cancer-free individuals (All < 0.01). The use of the three genes produced 81.1% sensitivity and 95.8% specificity in distinguishing NSCLC patients from both normal and COPD subjects. The plasma snoRNA expressions were not associated with stages and histological types of NSCLC (All > 0.05).ConclusionsThe identified snoRNAs provide potential markers for NSCLC early detection.

【 授权许可】

Unknown   
© Liao et al; licensee BioMed Central Ltd. 2010. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.